Diabetes drug tested to boost immune attack on liver cancer
NCT ID NCT02650427
Summary
This small, early-stage study tested if a diabetes medication called sitagliptin is safe for liver cancer patients before surgery. The goal was to see if the drug could help the body's immune cells better target and fight the tumor. Fourteen patients took the drug for three weeks before their scheduled liver tumor removal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pitié-Salpêtrière Hospital
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.